Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
HRTX similar filings
- 4 Oct 21 Other Events
- 24 Sep 21 Departure of Directors or Certain Officers
- 9 Aug 21 Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates
- 2 Aug 21 Changes in Registrant's Certifying Accountant
- 17 Jun 21 Submission of Matters to a Vote of Security Holders
- 25 May 21 Entry into a Material Definitive Agreement
- 13 May 21 Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
Filing view
External links
EXHIBIT 16.1
August 2, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549-7561
Ladies and Gentlemen:
We have read Heron Therapeutics, Inc.’s statements included under Item 4.01 of its Form 8‑K dated August 2, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K.
Very truly yours,
/s/ OUM & Co. LLP